INDICATED FOR THE TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.
RECOMMENDED DOSE IS 0.5 MG ORALLY ONCE-DAILY. FINGOLIMOD DOSES HIGHER THAN 0.5 MG ARE ASSOCIATED WITH A GREATER INCIDENCE OF ADVERSE REACTIONS WITHOUT ADDITIONAL BENEFIT.
PATIENTS WITH A PROLONGED QTC INTERVAL ( > 450 MSEC MALES, > 470 MSEC FEMALES) BEFORE DOSING OR DURING 6 HOUR OBSERVATION, OR AT ADDITIONAL RISK FOR QT PROLONGATION (E.G., HYPOKALEMIA, HYPOMAGNESEMIA, CONGENITAL LONG-QT SYNDROME), OR ON CONCURRENT THERAPY WITH QT PROLONGING DRUGS WITH A KNOWN RISK OF TORSADES DE POINTES (E.G., CITALOPRAM, CHLORPROMAZINE, HALOPERIDOL, METHADONE, ERYTHROMYCIN) SHOULD BE MONITORED OVERNIGHT WITH CONTINUOUS ECG IN A MEDICAL FACILITY.